MMJ currently maintains: two active FDA Investigational New Drug (IND) applications for Huntington's disease and multiple sclerosis; an FDA Orphan Drug Designation; a DEA Schedule I analytical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results